Circadian Technologies Ltd
Circadian Technologies Limited is listed on the Australian Stock Exchange and conducts research and development in the Australian biomedical sector. It seeks to access high potential research from within Australian universities and research institutes and to take it through to commercialisation.
Circadian maintains an active research and development program, with six current projects.
In addition to its research program, Circadian retains shareholdings in Optiscan Imaging, Metabolic Pharmaceuticals and Antisense Therapeutics, companies which Circadian has listed on the Australian Stock Exchange. Circadian is also the largest shareholder in Amrad Corporation and a major shareholder in Avexa Limited, both Australian pharmaceutical research and development companies.
Universities and Institutes, including Melbourne, Monash and Sydney Universities, Howard Florey Institute and WEHI.
- Ability to provide both funding and management resources for early stage biotech projects.
- Proven track record over 20 years in commercialising science.
- Highly focussed, virtual company with the ability to move quickly.
Circadian holds intellectual property across a broad field of interest. Current research projects include the development of a potential new treatment for Alzheimer's Disease, a new environmentally friendly process for manufacture of a key pharmaceutical raw material (ephedrine), identification of memory enhancing compounds based on specific brain receptors and development of new analgesics based on morphine but without the undesirable CNS side effects.
Currently seeking licensees for ephedrine process, memory enhancing compounds and analgesics.
|Contact person||Mr Robert Klupacs|
|Job Title||CEO & Managing Director|
|Address||10 Wallace Avenue|
|Phone||+61 3 9826 0399|
|Fax||+61 3 9824 0083|